Emerging insights on drug delivery by fatty acid mediated synthesis of lipophilic prodrugs as novel nanomedicines

J Control Release. 2020 Oct 10:326:556-598. doi: 10.1016/j.jconrel.2020.07.012. Epub 2020 Jul 26.

Abstract

Many drug molecules that are currently in the market suffer from short half-life, poor absorption, low specificity, rapid degradation, and resistance development. The design and development of lipophilic prodrugs can provide numerous benefits to overcome these challenges. Fatty acids (FAs), which are lipophilic biomolecules constituted of essential components of the living cells, carry out many necessary functions required for the development of efficient prodrugs. Chemical conjugation of FAs to drug molecules may change their pharmacodynamics/pharmacokinetics in vivo and even their toxicity profile. Well-designed FA-based prodrugs can also present other benefits, such as improved oral bioavailability, promoted tumor targeting efficiency, controlled drug release, and enhanced cellular penetration, leading to improved therapeutic efficacy. In this review, we discuss diverse drug molecules conjugated to various unsaturated FAs. Furthermore, various drug-FA conjugates loaded into various nanostructure delivery systems, including liposomes, solid lipid nanoparticles, emulsions, nano-assemblies, micelles, and polymeric nanoparticles, are reviewed. The present review aims to inspire readers to explore new avenues in prodrug design based on the various FAs with or without nanostructured delivery systems.

Keywords: Cancer therapy; Drug delivery; Fatty acids; Nanomedicine; Prodrugs.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Drug Delivery Systems
  • Fatty Acids
  • Nanomedicine
  • Nanoparticles*
  • Prodrugs*

Substances

  • Fatty Acids
  • Prodrugs